Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 85 to 86 of 86 entries
Sorted by: Best Match Show Resources per page
Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition.

The Journal of pharmacology and experimental therapeutics

Johnson CR, Kangas BD, Jutkiewicz EM, Winger G, Bergman J, Coop A, Woods JH.
PMID: 33712507
J Pharmacol Exp Ther. 2021 Jun;377(3):336-345. doi: 10.1124/jpet.120.000337. Epub 2021 Mar 12.

The cholinergic nervous system has been implicated in mood disorders, evident in the fast-onset antidepressant effects of scopolamine, a potent muscarinic antagonist, in clinical studies. One prominent disadvantage of the use of scopolamine in the treatment of depression is...

Cite
Johnson CR, Kangas BD, Jutkiewicz EM, et al. Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition. J Pharmacol Exp Ther. 2021;377(3):336-345doi: 10.1124/jpet.120.000337.
Johnson, C. R., Kangas, B. D., Jutkiewicz, E. M., Winger, G., Bergman, J., Coop, A., & Woods, J. H. (2021). Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition. The Journal of pharmacology and experimental therapeutics, 377(3), 336-345. https://doi.org/10.1124/jpet.120.000337
Johnson, Chad R, et al. "Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition." The Journal of pharmacology and experimental therapeutics vol. 377,3 (2021): 336-345. doi: https://doi.org/10.1124/jpet.120.000337
Johnson CR, Kangas BD, Jutkiewicz EM, Winger G, Bergman J, Coop A, Woods JH. Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition. J Pharmacol Exp Ther. 2021 Jun;377(3):336-345. doi: 10.1124/jpet.120.000337. Epub 2021 Mar 12. PMID: 33712507; PMCID: PMC8140394.
Copy Download .nbib Format: NLM
Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease.

Journal of experimental pharmacology

Ora J, Coppola A, Cazzola M, Calzetta L, Rogliani P.
PMID: 33324119
J Exp Pharmacol. 2020 Dec 08;12:559-574. doi: 10.2147/JEP.S259330. eCollection 2020.

INTRODUCTION: Bronchodilators are the cornerstone of chronic obstructive pulmonary disease (COPD) therapy and long-acting muscarinic antagonists (LAMAs) as a mono or combination treatment play a pivotal role. Several LAMAs are already available on the market in different formulations, but...

Cite
Ora J, Coppola A, Cazzola M, et al. Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease. J Exp Pharmacol. 2020;12:559-574doi: 10.2147/JEP.S259330.
Ora, J., Coppola, A., Cazzola, M., Calzetta, L., & Rogliani, P. (2020). Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease. Journal of experimental pharmacology, 12559-574. https://doi.org/10.2147/JEP.S259330
Ora, Josuel, et al. "Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease." Journal of experimental pharmacology vol. 12 (2020): 559-574. doi: https://doi.org/10.2147/JEP.S259330
Ora J, Coppola A, Cazzola M, Calzetta L, Rogliani P. Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease. J Exp Pharmacol. 2020 Dec 08;12:559-574. doi: 10.2147/JEP.S259330. eCollection 2020. PMID: 33324119; PMCID: PMC7733406.
Copy Download .nbib Format: NLM
Showing 85 to 86 of 86 entries